Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. (“EpiVax”). Chugai, one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in ...

Providence, R.I., May 28, 2019 – EpiVax, Inc. is celebrating the company’s 21st birthday in Providence by renewing its commitment to improving human health everywhere and highlighting the work of two not-for-profit organizations that have been partners with EpiVax for nearly all of those 21 years. Clínica Esperanza/Hope Clinic (CEHC) is located near EpiVax’s headquarters in ...

THIS ORIGINAL ARTICLE WAS PUBLISHED IN PR NEWSWIRE. LINK TO THE ORIGINAL ARTICLE CAN BE FOUND HERE. NEW YORK, March 25, 2019 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an oral presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, taking place on March ...

Making Epi-Resolutions for 2019: In 2019, EpiVax will strive to help improve human-to-human interactions, while supporting the right of every human to speak freely, to be healthy, to build diverse communities and to wage peace. We will also promote humane practices towards animals and work to protect and honor the Earth, our home. And, of course, ...

Leslie J. DeGroot MD (“Les”) was born on a dairy farm in Fort Edward NY in 1928, dedicated his life to thyroid disease research and endocrinology and died soon after his 90th birthday, on October 23, 2018 in Nonquitt, Massachusetts, surrounded by his many loving grandchildren, children and his wife.

This original article was published on October 2nd, 2018 in ConvergenceRI. PROVIDENCE, RI – The U.S. Food and Drug Administration announced on Tuesday, Oct. 2, that the federal agency has awarded EpiVax and CUBRC a $1 million contract over two years to establish best practices and procedures to evaluate generic peptide drugs for immunogenic potential and related ...

EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and related impurities for immunogenic potential.

NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC. EpiVax Oncology, Inc. (EO) is developing precision cancer immunotherapies based on Neo-Epitopes ...

PROVIDENCE, R.I., June 11, 2018 — EpiVax announces their move to a new headquarters at 188 Valley Street, in the “Rising Sun” complex, a former wool mill in the Olneyville section of Providence, Rhode Island. The privately held bioinformatics company is also celebrating its 20th anniversary. The mission of EpiVax is to “improve human health everywhere” through ...

PROVIDENCE, R.I., May 18, 2018 /PRNewswire/ — The National Institutes of Health (NIH) has awarded EpiVax, Inc. (“EpiVax”), experts in the field of immunogenicity risk assessment, a $324,980 Small Business Innovation Research (SBIR) grant. The funding will enable EpiVax to further develop the new Personalized Immunogenicity Assessment (PIMA) tool, for the individualized risk assessment of ...

PROVIDENCE, R.I., March 9, 2018 /PRNewswire/ — EpiVax Inc., (“EpiVax”) an innovative Rhode Island-based biotechnology company, has a lot to celebrate on International Women’s Day. The company, founded and led by Dr. Annie De Groot, boasts a female-majority work force and appears multiple times in the Providence Business News Book of Lists for Rhode Island: Top Private Companies (by revenue), Fastest ...

EpiVax Awarded Grant to Develop New Graves' Disease Therapy

EpiVax Oncology Press Release Sept 25 2017 Sept 25, 2017 (Providence, RI) – EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. EpiVax has provided $500,000 in seed funding and has provided ...

$5.8 MILLION AWARDED FOR VACCINE ENGINEERING WILL USE “IMMUNE HISTORY” TO PROTECT AGAINST BIRD FLU, A COLLABORATION LED BY EPIVAX   PROVIDENCE, R.I., Sept. 18, 2017– EpiVax, Inc. (“EpiVax”) a pioneer in the fields of bioinformatics and immune engineering, today announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine. H7N9 is distantly related to seasonal influenza ...

EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called EpiVax Oncology. EpiVax Oncology Inc. is a newly created, wholly owned subsidiary of EpiVax Inc. ...